Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$47.03

0.32 (0.69%)

07:02
10/03/16
10/03
07:02
10/03/16
07:02

Alkermes announces initiation of ALKS 3831 study for schizophrenia treatment

Alkermes announced the initiation of a clinical study designed to evaluate the metabolic profile of ALKS 3831, an investigational, novel, oral atypical antipsychotic drug candidate, compared to olanzapine, an established atypical antipsychotic agent with proven efficacy but also metabolic liabilities, including significant weight gain. The randomized, double-blind, parallel-group study will characterize metabolic parameters, including insulin sensitivity and lipid metabolism, in response to treatment with ALKS 3831 and olanzapine. This exploratory metabolic study in healthy subjects is a supportive study in the ENLIGHTEN pivotal program of ALKS 3831 for the treatment of schizophrenia. The two key phase 3 studies, ENLIGHTEN-1 and ENLIGHTEN-2, have been enrolling patients since December 2015 and February 2016, respectively. The objective of the newly-initiated metabolic study is to more fully characterize the comparative metabolic effects of ALKS 3831 and olanzapine, in order to understand the potential metabolic benefits of ALKS 3831 and to build on the findings from previously conducted preclinical and clinical studies that suggest treatment with ALKS 3831 is associated with less weight gain compared to olanzapine. ALKS 3831 is designed to provide patients with the strong efficacy of olanzapine with favorable weight and metabolic properties. The phase 1 metabolic study will assess the effects of ALKS 3831 on whole body insulin sensitivity, lipid metabolism and other important metabolic parameters compared to olanzapine. Approximately 50 healthy subjects will be randomized to receive ALKS 3831, olanzapine or placebo for 21 days. Results from the study are expected in the first half of 2017.

  • 06

    Nov

ALKS Alkermes
$47.03

0.32 (0.69%)

07/29/16
FBCO
07/29/16
NO CHANGE
Target $52
FBCO
Outperform
Alkermes quarter raised some questions, says Credit Suisse
Credit Suisse analyst Vamil Divan says Alkermes' Q2 results, while solid overall, raised some questions. The stock came under pressure yesterday given some questions around net pricing for Vivitrol as well development timelines around ALKS 8700, Divan tells investors in a post-earnings research note. Vivitrol sales slightly missed what some investors were hoping for since an increased percentage of volume came at lower net prices from Medicaid customers, the analyst contends. Divan remains bullish on the overall story and views the stock's risk/reward as attractive ahead of the FORWARD-5 data by year-end. He raised his price target for the shares to $52 from $45 and keeps an Outperform rating on Alkermes.
07/29/16
COWN
07/29/16
NO CHANGE
Target $60
COWN
Outperform
Alkermes weakness a buying opportunity, says Cowen
Cowen said the weakness in Alkermes is a buying opportunity as they believe the magnitude, sustainability, and impact of Vivitrol's growth is being meaningfully underestimated by the Street. Cowen reiterated its Outperform rating and $60 price target on Alkermes shares.
09/27/16
SBSH
09/27/16
NO CHANGE
Target $53
SBSH
Neutral
Alkermes price target raised to $53 from $44 at Citi
Citi analyst Liav Abraham raised her price target for Alkermes to $53 after the company hosted an investor event to overview the various aspects of Vivitrol. Alkermes' execution on a "unique commercial model," which targets the differing opioid addiction population needs on a state-by-state basis, is likely to drive robust volume growth going forward, particularly in the Medicaid patient population, Abraham tells investors in a research note. The analyst raised her estimates for Vivitrol but remains cautious on the FORWARD-5 data for ALKS 5461 due out in Q4. As such, Abraham keeps a Neutral rating on Alkermes.
09/27/16
JEFF
09/27/16
NO CHANGE
Target $62
JEFF
Buy
Alkermes sees significant room for Vivitrol upside, says Jefferies
Alkermes yesterday at its Vivitrol-focused event highlighted that the opioid treatment is still in the early stages of growth, Jefferies analyst Biren Amin tells investors in a research note. The company estimates that Vivitrol is currently capturing only 2% average market share and believes room for upside is significant, the analyst writes. He keeps a Buy rating on Alkermes with a $62 price target.

TODAY'S FREE FLY STORIES

14:00
04/28/17
04/28
14:00
04/28/17
14:00
General news
FX Action: USD-JPY »

FX Action: USD-JPY got a…

13:56
04/28/17
04/28
13:56
04/28/17
13:56
General news
Stocks remain in narrow range »

Stocks are generally…

13:55
04/28/17
04/28
13:55
04/28/17
13:55
General news
Action Economics Survey results: »

Action Economics Survey…

T

AT&T

$39.69

-0.22 (-0.55%)

13:52
04/28/17
04/28
13:52
04/28/17
13:52
Hot Stocks
AT&T invested nearly $7.2B in California wireless and wired networks »

AT&T invested nearly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 09

    May

  • 16

    May

  • 17

    May

LL

Lumber Liquidators

$24.50

0.14 (0.57%)

13:51
04/28/17
04/28
13:51
04/28/17
13:51
Options
Bullish earnings play in Lumber Liquidators »

Bullish earnings play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

QCOM

Qualcomm

$53.21

0.17 (0.32%)

, AAPL

Apple

$143.79

0.11 (0.08%)

13:50
04/28/17
04/28
13:50
04/28/17
13:50
Recommendations
Qualcomm, Apple analyst commentary  »

Oppenheimer doesn't…

QCOM

Qualcomm

$53.21

0.17 (0.32%)

AAPL

Apple

$143.79

0.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 08

    May

SPY

SPDR S&P 500 ETF Trust

$238.16

-0.44 (-0.18%)

, IVV

iShares Core S&P 500

$239.68

-0.41 (-0.17%)

13:46
04/28/17
04/28
13:46
04/28/17
13:46
Technical Analysis
On The Fly: ETF fund flow highlights »

Per data from ETF.com,…

SPY

SPDR S&P 500 ETF Trust

$238.16

-0.44 (-0.18%)

IVV

iShares Core S&P 500

$239.68

-0.41 (-0.17%)

VOO

Vanguard S&P 500 ETF

$218.65

-0.37 (-0.17%)

IWM

iShares Trust Russell 2000 Index Fund

$139.61

-1.34 (-0.95%)

QQQ

PowerShares QQQ Trust

$135.75

0.81 (0.60%)

XLF

Financial Select Sector

$23.62

-0.145 (-0.61%)

IEMG

iShares Core MSCI Emerging Markets

$48.67

0.065 (0.13%)

EZU

iShares MSCI Eurozone ETF

$39.33

0.0493 (0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$122.08

-0.04 (-0.03%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$88.16

0.01 (0.01%)

XLP

Consumer Staples Sector SPDR

$55.11

-0.09 (-0.16%)

VNQ

Vanguard REIT Index Fund

$82.86

-0.8037 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPN

Calpine

$10.00

0.41 (4.28%)

13:31
04/28/17
04/28
13:31
04/28/17
13:31
Options
Calpine calls active after earnings »

Calpine calls active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
04/28/17
04/28
13:30
04/28/17
13:30
General news
NY Fed accepted $181.98 B in daily reverse repos »

NY Fed accepted $181.98 B…

ALDR

Alder Biopharmaceuticals

$21.35

-0.8 (-3.61%)

13:25
04/28/17
04/28
13:25
04/28/17
13:25
Hot Stocks
Alder Biopharmaceuticals presents 'positive' Phase 2b data for Eptinezumab »

Alder BioPharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

OCN

Ocwen

$2.26

0.03 (1.35%)

13:22
04/28/17
04/28
13:22
04/28/17
13:22
Periodicals
CFPB was seeking Ocwen settlement in $50M range, IMF reports »

The Consumer Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

BCEI

Bonanza Creek

$0.79

0.0099 (1.27%)

13:21
04/28/17
04/28
13:21
04/28/17
13:21
Hot Stocks
Breaking Hot Stocks news story on Bonanza Creek »

Bonanza Creek trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

13:17
04/28/17
04/28
13:17
04/28/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
04/28/17
04/28
13:16
04/28/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAN

Banco Santander

$6.53

0.08 (1.24%)

13:16
04/28/17
04/28
13:16
04/28/17
13:16
Options
Banco Santander put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:15
04/28/17
04/28
13:15
04/28/17
13:15
General news
Energy Action: Baker-Hughes »

Energy Action:…

BCEI

Bonanza Creek

$0.79

0.0099 (1.27%)

13:10
04/28/17
04/28
13:10
04/28/17
13:10
Hot Stocks
Bonanza Creek announces emergence from Chapter 11 bankruptcy »

Bonanza Creek Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:06
04/28/17
04/28
13:06
04/28/17
13:06
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 4/28 Baker-Hughes…

MSI

Motorola Solutions

$85.88

-0.19 (-0.22%)

13:04
04/28/17
04/28
13:04
04/28/17
13:04
Hot Stocks
Motorola Solutions: ITC to probe unfair trade practices by Hytera »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 31

    May

BCEI

Bonanza Creek

$0.79

0.0049 (0.63%)

13:03
04/28/17
04/28
13:03
04/28/17
13:03
Hot Stocks
Breaking Hot Stocks news story on Bonanza Creek »

Bonanza Creek trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHI

Baker Hughes

$59.34

-0.31 (-0.52%)

13:03
04/28/17
04/28
13:03
04/28/17
13:03
Hot Stocks
Baker Hughes reports U.S. rig count up 13 to 870 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBP

Huttig Building Products

$9.03

0.28 (3.20%)

13:01
04/28/17
04/28
13:01
04/28/17
13:01
Hot Stocks
Huttig Building announces national distribution pact with Knauf Insulation »

Huttig Building Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

13:00
04/28/17
04/28
13:00
04/28/17
13:00
General news
Breaking General news story  »

Federal Reserve Board of…

HNHPF

Hon Hai Precision

12:59
04/28/17
04/28
12:59
04/28/17
12:59
Periodicals
Foxconn to invest in U.S., Reuters reports »

Terry Gou, chairman of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$106.48

-0.015 (-0.01%)

12:51
04/28/17
04/28
12:51
04/28/17
12:51
Options
$7.7M vote of confidence in iShares 7 to 10 year Treasury Bond ETF »

$7.7M vote of confidence…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.